[go: up one dir, main page]

EA200201008A1 - Получение рекомбинантных факторов свертывания крови в линиях клеток человека - Google Patents

Получение рекомбинантных факторов свертывания крови в линиях клеток человека

Info

Publication number
EA200201008A1
EA200201008A1 EA200201008A EA200201008A EA200201008A1 EA 200201008 A1 EA200201008 A1 EA 200201008A1 EA 200201008 A EA200201008 A EA 200201008A EA 200201008 A EA200201008 A EA 200201008A EA 200201008 A1 EA200201008 A1 EA 200201008A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human cells
factor viii
promoter
factor
blood collection
Prior art date
Application number
EA200201008A
Other languages
English (en)
Other versions
EA004317B1 (ru
Inventor
Шарлотта Хаузер
Андреа Херстер
Карола Шредер
Михель Ленерер
Original Assignee
Октагене Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Октагене Гмбх filed Critical Октагене Гмбх
Publication of EA200201008A1 publication Critical patent/EA200201008A1/ru
Publication of EA004317B1 publication Critical patent/EA004317B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к усовершенствованному способу получения рекомбинантных факторов свертывания крови человека, в частности фактора VIII и фактора IX, с использованием линии иммортализованных клеток человека, стабильно экспрессирующих вирусные белки активаторов транскрипции и несущих вектор, имеющий промотор, функционально связанный с последовательностью ДНК, кодирующей коагулирующий фактор крови, при условии, что указанный промотор не является вирусным промотором, который стимулируется указанными вирусными белками активаторов транскрипции; к линии иммортализованных клеток человека, несущих указанный вектор; к мутеинам фактора VIII, особенно подходящим для указанного выше способа получения; к фармацевтическим композициям, содержащим такие мутеины фактора VIII, и к применению указанных мутеинов фактора VIII для получения лекарственного средства для лечения гемофилии.Отчет о международном поиске был опубликован 2001.12.13.
EA200201008A 2000-03-22 2001-03-21 Получение рекомбинантных факторов свертывания крови в линиях клеток человека EA004317B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (en) 2000-03-22 2001-03-21 Production of recombinant blood clotting factors in human cell lines

Publications (2)

Publication Number Publication Date
EA200201008A1 true EA200201008A1 (ru) 2003-02-27
EA004317B1 EA004317B1 (ru) 2004-02-26

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201008A EA004317B1 (ru) 2000-03-22 2001-03-21 Получение рекомбинантных факторов свертывания крови в линиях клеток человека

Country Status (28)

Country Link
US (1) US7572619B2 (ru)
EP (2) EP1460131A3 (ru)
JP (1) JP3894795B2 (ru)
KR (1) KR100581574B1 (ru)
CN (1) CN1454257B (ru)
AT (1) ATE312176T1 (ru)
AU (3) AU5471501A (ru)
BE (1) BE2014C077I2 (ru)
BG (1) BG65930B1 (ru)
BR (1) BRPI0109494B8 (ru)
CA (1) CA2404163C (ru)
CZ (1) CZ303929B6 (ru)
DE (1) DE60115613T2 (ru)
DK (1) DK1266006T3 (ru)
EA (1) EA004317B1 (ru)
EE (1) EE200200538A (ru)
ES (1) ES2254403T3 (ru)
FR (1) FR15C0003I2 (ru)
HR (1) HRP20020767B1 (ru)
HU (1) HU228091B1 (ru)
IL (2) IL151857A0 (ru)
MX (1) MXPA02009221A (ru)
NO (1) NO330910B1 (ru)
NZ (1) NZ521732A (ru)
RS (1) RS50743B (ru)
SI (1) SI1266006T1 (ru)
SK (1) SK287706B6 (ru)
WO (1) WO2001070968A2 (ru)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151857A0 (en) * 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
HUP0301179A3 (en) * 2000-09-19 2006-11-28 Univ Emory Modified factor viii
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
ATE489105T1 (de) * 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
ATE549037T1 (de) 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US8530192B2 (en) * 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
CA3090908A1 (en) * 2007-04-26 2008-11-06 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
JPWO2009028575A1 (ja) * 2007-08-27 2010-12-02 国立大学法人名古屋大学 血液凝固第ｖｉｉ因子プロモーターの活性化剤及びその利用
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
ES2717902T5 (es) 2009-10-02 2022-11-29 Childrens Hospital Philadelphia Composiciones y procedimientos para mejorar la función del factor VIII de coagulación
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
BRPI1105317A2 (pt) 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
CA2827923C (en) 2011-02-25 2021-11-23 Chugai Seiyaku Kabushiki Kaisha Fc.gamma.riib-specific fc antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
WO2012156356A1 (en) 2011-05-13 2012-11-22 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
KR20140084208A (ko) 2011-10-18 2014-07-04 시에스엘 리미티드 정제된 인자 ｖｉｉｉ의 재구성 후의 안정성을 향상시키는 방법
WO2013075066A2 (en) 2011-11-18 2013-05-23 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
BR112014013081A2 (pt) 2011-11-30 2020-10-20 Chugai Seiyaku Kabushiki Kaisha veículo contendo fármaco em célula para formação de um complexo imune
EP2825556B1 (en) 2012-03-16 2018-01-03 Albumedix A/S Albumin variants
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
KR20150082422A (ko) 2012-11-08 2015-07-15 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
CA2898975C (en) * 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
EA035581B1 (ru) * 2014-07-30 2020-07-10 НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК. Композиции и способы применения для лечения метаболических расстройств
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
CN109562191A (zh) 2016-04-15 2019-04-02 宾夕法尼亚州大学信托人 用于治疗血友病a的基因疗法
CA3026050A1 (en) 2016-08-05 2018-02-08 Chugai Seiyaku Kabushiki Kaisha Composition for prophylaxis or treatment of il-8 related diseases
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
WO2020032230A1 (ja) 2018-08-10 2020-02-13 中外製薬株式会社 抗ｃｄ１３７抗原結合分子およびその使用
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
CN113301911B (zh) 2018-10-23 2025-07-15 费城儿童医院 用于调节因子viii功能的组合物和方法
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
EP0253870B1 (en) * 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
KR927003812A (ko) * 1989-11-17 1992-12-18 노보 노르디스크 아크티에 셀스카브 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
ATE103982T1 (de) * 1990-01-26 1994-04-15 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
CA2162497A1 (en) * 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
CA2312291A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1151099A1 (en) * 1999-02-19 2001-11-07 Octagene GmbH Hormone-hormone receptor complexes and nucleic acid constructs and their use in gene therapy
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
IL151857A0 (en) * 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Also Published As

Publication number Publication date
BRPI0109494B1 (pt) 2021-05-11
EP1266006A2 (en) 2002-12-18
CZ303929B6 (cs) 2013-07-03
DK1266006T3 (da) 2006-01-16
FR15C0003I1 (fr) 2015-02-27
CZ20023166A3 (cs) 2003-02-12
AU2001254715B2 (en) 2006-02-02
HUP0300588A2 (hu) 2003-06-28
BG65930B1 (bg) 2010-05-31
SK15042002A3 (sk) 2003-09-11
EP1460131A3 (en) 2005-06-01
NZ521732A (en) 2004-05-28
AU2006201848A1 (en) 2006-05-25
NO20024475D0 (no) 2002-09-19
AU5471501A (en) 2001-10-03
SI1266006T1 (sl) 2006-06-30
YU71002A (sh) 2005-11-28
HU228091B1 (en) 2012-10-29
EP1266006B1 (en) 2005-12-07
BE2014C077I2 (ru) 2020-01-30
BR0109494A (pt) 2002-12-10
HRP20020767B1 (hr) 2011-09-30
KR20030011079A (ko) 2003-02-06
NO20024475L (no) 2002-11-20
DE60115613T2 (de) 2006-08-24
IL151857A0 (en) 2003-04-10
CN1454257B (zh) 2013-01-16
RS50743B (sr) 2010-08-31
KR100581574B1 (ko) 2006-05-22
HRP20020767A2 (en) 2005-02-28
BRPI0109494B8 (pt) 2021-05-25
ATE312176T1 (de) 2005-12-15
EE200200538A (et) 2004-04-15
FR15C0003I2 (fr) 2015-11-20
US20040023333A1 (en) 2004-02-05
DE60115613D1 (de) 2006-01-12
ES2254403T3 (es) 2006-06-16
EP1460131A2 (en) 2004-09-22
US7572619B2 (en) 2009-08-11
WO2001070968A3 (en) 2001-12-13
CA2404163A1 (en) 2001-09-27
NO330910B1 (no) 2011-08-15
EA004317B1 (ru) 2004-02-26
IL151857A (en) 2010-05-31
CN1454257A (zh) 2003-11-05
CA2404163C (en) 2009-09-29
WO2001070968A2 (en) 2001-09-27
JP3894795B2 (ja) 2007-03-22
JP2003530093A (ja) 2003-10-14
SK287706B6 (en) 2011-07-06
HUP0300588A3 (en) 2005-09-28
BG107152A (bg) 2003-06-30
MXPA02009221A (es) 2005-07-25

Similar Documents

Publication Publication Date Title
EA200201008A1 (ru) Получение рекомбинантных факторов свертывания крови в линиях клеток человека
AU645539B2 (en) A recombinant human factor VIII derivative
RU2002124123A (ru) Модифицированный фактор viii
ATE309360T1 (de) Vaskularer endothelialer wachstumsfaktor 2
CA2323073A1 (en) Uses for human non-autologous mesenchymal stem cells
DE68919229D1 (de) Hybride prokoagulierende proteine.
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
KR890000666A (ko) 응고활성을 갖는 인자 viii:c-형 분자
US5900476A (en) Therapeutic domains of van Willebrand factor
DE60125563D1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
ES8607730A1 (es) Procedimiento para producir el factor viii-c humano
JP2872255B2 (ja) ファクター▲ｖｉｉｉ▼の高収量生産法
KR890006815A (ko) 산성 섬유아세포 생장인자의 돌연변이체
JPH0570364A (ja) 骨への破骨細胞付着を阻害する組成物及び方法
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
JP2907447B2 (ja) 抗血栓剤
ES2312228B1 (es) Epidermis cultivada secretora de factores terapeuticos producida por celulas madre de pelo y metodo de obtencion.
FI109766B (fi) Menetelmä eskaraasia sisältävän proteolyyttisen seoksen valmistamiseksi
AU625914B2 (en) Thrombus agent control
BG106513A (en) New class of bioactive glycoproteins
CO4480761A1 (es) Metodo para movilizar celulas tronco hematopoyeticas

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

TC4A Change in name of a patent proprietor in a eurasian patent

Designated state(s): BY RU

PC4A Registration of transfer of a eurasian patent by assignment
ND4A Extension of term of a eurasian patent